The main objective of this study is to understand that Type 2 diabetes (T2DM) has been appeared to build the danger of Alzheimer’s infection (AD).1 The reason for this isn’t completely perceived, albeit sped up amassing of misfolded amyloid beta (Aβ) and hyperphosphorylated tau (p‐tau) proteins,2 and cerebrum insulin opposition have been proposed.3 Widespread changes in cortical glucose digestion are found in AD, and it has been recommended that oral hypoglycemic (anti‐diabetic) specialists might be of benefit.3

Most of past observational examinations have researched relationship between a particular medication class and dementia hazard in individuals with T2DM who were psychologically typical at baseline.4 Fewer investigations have considered connections between various medication classes and memory changes in intellectually ordinary individuals with T2DM,5, 6 or among individuals with T2DM who additionally have a determination of AD dementia. Metformin has been related with a lower dementia risk;4 in any case, its impacts on memory have been inconsistent.5, 6 Relatively hardly any clinical investigations have evaluated relationship among memory and dipeptidyl peptidase‐4 (DPP4) inhibitor use,7, 8 despite the fact that sitagliptin, a DPP4 inhibitor, was related with improved general cognizance in individuals with T2DM and AD,9 and was appeared to moderate Aβ amassing in transgenic mouse models of AD.

Reference link- https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12161

Author